CIPLACipla
Pharma · Pharmaceuticals · NSE · as of 2026-09-11 (delayed ~30 min in market hours)
Cipla operates in the Pharmaceuticals space within the Pharma sector.
Price & Volume
Loading chart…
Key Ratios
“—” means the figure isn't meaningful or isn't published for this company: ROE and Debt/Equity are undefined when shareholder equity is negative (check P/B — negative means negative equity), and DII/MF holding splits aren't provided by our current data source.
Active Pattern Signals
None of the 16 pattern scanners currently detects a setup on CIPLA — signals appear here automatically when one forms (checked on every data refresh). The Trade Plan on the right always provides stop-loss and target levels regardless.
The picture
- • Debt/Equity: 0.02
- • Valuation vs sector: P/E 32.8 vs sector 40.5
- • Golden cross setup: SMA50 above SMA200
- • Volume: 2.1x 20-day average
- • 6-month vs NIFTY: +8.4% relative
- • Sector momentum: sector +6.2% (1m)
Bull case
- • Debt/Equity: 0.02
- • Valuation vs sector: P/E 32.8 vs sector 40.5
- • Golden cross setup: SMA50 above SMA200
- • Volume: 2.1x 20-day average
Bear case
- • Revenue growth: 3.5% YoY
- • Profit growth: -39.2% YoY
- • RSI: 35
- • MACD: bearish
Key risks
- • Weak fundamentals — technical strength may not sustain
- • Revenue growth: 3.5% YoY
- • Profit growth: -39.2% YoY
Algorithmic analysis for research only — not SEBI-registered investment advice.
Trade Plan
Stop = 20-day support with a 2.5×ATR risk cap (ATR ₹22.52). Levels recompute on every data refresh. Position sizing and execution are yours — this is analysis, not advice.